Compare American Airlines Group Inc (AAL) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Airlines Group Inc vs Quest Diagnostics Inc — how do they compare? American Airlines Group Inc trades at $16.61 (market cap $11.38B), while Quest Diagnostics Inc trades at $208.01 (market cap $23.51B). The key difference: Quest Diagnostics Inc is far larger — about 2.1× American Airlines Group Inc's market cap, and Quest Diagnostics Inc pays a 1.62% dividend while American Airlines Group Inc pays none. Which is the better fit depends on your goals.
| AAL | DGX | |
|---|---|---|
Market Cap | $11.38B | $23.51B |
Sector | Industrials | Health |
52-Week High | $18.15 | $216.02 |
52-Week Low | $10.18 | $166.42 |
Enterprise Value | $38.97B | $29.52B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.
Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.
Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.
DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
